Monte Rosa Total Cash From Financing Activities Over Time
| GLUE Stock | USD 8.35 0.01 0.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Monte Rosa Performance and Monte Rosa Correlation. Monte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Financing Activities Analysis
Compare Monte Rosa Therapeutics and related stocks such as Nkarta Inc, Lyell Immunopharma, and Generation Bio Total Cash From Financing Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTX | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 87.5 K | 49.6 M | 329.8 M | 1.2 M | 219 M | 691 K | 656.5 K |
| LYEL | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 351.2 M | 476.8 M | 401.2 M | 10.6 M | 1.7 M | 1.7 M |
| GBIO | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 100.2 M | 78 K | 323.1 M | 214.7 M | 13 M | 35.8 M | 34 M |
| SANA | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 223.7 M | 435.7 M | 631.8 M | 4.9 M | 31.6 M | 30.1 M |
| DSGN | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 196 K | 44.5 M | 379.2 K | 235 | 724 K | 687.8 K |
| HOWL | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 93.9 M | 109.4 M | 15.9 M | 58.4 M | 47.9 M |
| IKNA | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 116.2 M | 131.7 M | 1.1 M | 76 M | 65.6 M |
| STOK | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 115.6 M | 149.8 M | 108.1 M | 1.3 M | 46.4 M | 53 M | 54.9 M |
| FHTX | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 24 M | 217.5 M | 22.4 M | 1.8 M | 1.8 M | 1.7 M |
| STTK | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | (64 K) | 330.9 M | 1.9 M | 171 K | 48.6 M | 55.6 M |
| KYMR | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 34.9 M | 289.3 M | 250.3 M | 153 M | 4.2 M | 4 M |
| NRIX | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 126 K | 339 M | 153.9 M | 117.2 M | 3.2 M | 3.7 M | 3.5 M |
| ERAS | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 140 M | 439.4 M | 98.1 M | 1.3 M | 1.2 M |
Monte Rosa Therapeutics and related stocks such as Nkarta Inc, Lyell Immunopharma, and Generation Bio Total Cash From Financing Activities description
My Equities
My Current Equities and Potential Positions
| Monte Rosa Therapeutics | GLUE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.35
Check out Monte Rosa Performance and Monte Rosa Correlation. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Monte Rosa technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.